| Report Title | Price | Action |
|---|---|---|
| CNS Lymphoma (Oncology) - Drugs in Development, 2021
CNS Lymphoma (Oncology) - Drugs in Development, 2021 Summary CNS Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the CNS Ly...
Published: Apr-2021 | No. of Pages: 30
|
$ 2000 | |
| Reverse Transcriptase (EC 2.7.7.49) - Drugs in Development, 2021
Reverse Transcriptase (EC 2.7.7.49) - Drugs in Development, 2021 Summary Reverse Transcriptase (EC 2.7.7.49) - Drugs in Development, 2021 provides i...
Published: Apr-2021 | No. of Pages: 100
|
$ 3000 | |
| Transforming Growth Factor Beta 3 (TGFB3) - Drugs in Development, 2021
Transforming Growth Factor Beta 3 (TGFB3) - Drugs in Development, 2021 Summary Transforming Growth Factor Beta 3 (TGFB3) - Drugs in Development, 202...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Drugs in Development, 2021
Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Drugs in Development, 2021 Summ...
Published: Apr-2021 | No. of Pages: 35
|
$ 3000 | |
| Malignant Ascites (Oncology) - Drugs in Development, 2021
Malignant Ascites (Oncology) - Drugs in Development, 2021 Summary Malignant Ascites (Oncology) - Drugs in Development, 2021 provides an overview of ...
Published: Apr-2021 | No. of Pages: 30
|
$ 2000 | |
| Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R) - Drugs in Development, 2021
Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R) - Drugs in Development, 2021 Summary Granulocyte Colony Stimulating Factor ...
Published: Apr-2021 | No. of Pages: 105
|
$ 3000 | |
| Triggering Receptor Expressed On Myeloid Cells 1 (Triggering Receptor Expressed On Monocytes 1 or CD354 or TREM1) - Drugs in Development, 2021
Triggering Receptor Expressed On Myeloid Cells 1 (Triggering Receptor Expressed On Monocytes 1 or CD354 or TREM1) - Drugs in Development, 2021 Summar...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drugs in Development, 2021
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drugs in Developm...
Published: Apr-2021 | No. of Pages: 90
|
$ 3000 | |
| Mast Cell Leukemia (Oncology) - Drugs in Development, 2021
Mast Cell Leukemia (Oncology) - Drugs in Development, 2021 Summary Mast Cell Leukemia (Oncology) - Drugs in Development, 2021 provides an overview o...
Published: Apr-2021 | No. of Pages: 30
|
$ 2000 | |
| Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) - Drugs in Development, 2021
Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) - Drugs in Developmen...
Published: Apr-2021 | No. of Pages: 105
|
$ 3000 | |
| Tyrosyl DNA Phosphodiesterase 1 (TDP1 or EC 3.1.4.) - Drugs in Development, 2021
Tyrosyl DNA Phosphodiesterase 1 (TDP1 or EC 3.1.4.) - Drugs in Development, 2021 Summary Tyrosyl DNA Phosphodiesterase 1 (TDP1 or EC 3.1.4.) - Drugs...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in...
Published: Apr-2021 | No. of Pages: 55
|
$ 3000 | |
| Metastatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021
Metastatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021 Summary Metastatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021 prov...
Published: Apr-2021 | No. of Pages: 30
|
$ 2000 | |
| Delta Type Opioid Receptor (DOR1 or OPRD or OPRD1) - Drugs in Development, 2021
Delta Type Opioid Receptor (DOR1 or OPRD or OPRD1) - Drugs in Development, 2021 Summary Delta Type Opioid Receptor (DOR1 or OPRD or OPRD1) - Drugs i...
Published: Apr-2021 | No. of Pages: 105
|
$ 3000 | |
| Ubiquitin Carboxyl Terminal Hydrolase 30 (Deubiquitinating Enzyme 30 or Ubiquitin Thioesterase 30 or Ubiquitin Specific Processing Protease 30 or Ub Specific Protease 30 or USP30 or EC 3.4.19.12) - Drugs in Development, 2021
Ubiquitin Carboxyl Terminal Hydrolase 30 (Deubiquitinating Enzyme 30 or Ubiquitin Thioesterase 30 or Ubiquitin Specific Processing Protease 30 or Ub S...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Drugs in Development, 2021
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13...
Published: Apr-2021 | No. of Pages: 35
|
$ 3000 | |
| Pancreatic Ductal Carcinoma (Oncology) - Drugs in Development, 2021
Pancreatic Ductal Carcinoma (Oncology) - Drugs in Development, 2021 Summary Pancreatic Ductal Carcinoma (Oncology) - Drugs in Development, 2021 prov...
Published: Apr-2021 | No. of Pages: 30
|
$ 2000 | |
| DNA Topoisomerase I (TOP1 or EC 5.99.1.2) - Drugs in Development, 2021
DNA Topoisomerase I (TOP1 or EC 5.99.1.2) - Drugs in Development, 2021 Summary DNA Topoisomerase I (TOP1 or EC 5.99.1.2) - Drugs in Development, 202...
Published: Apr-2021 | No. of Pages: 105
|
$ 3000 | |
| Vasoactive Intestinal Polypeptide Receptor 2 (Helodermin Preferring VIP Receptor or Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor or VPAC2 or VIPR2) - Drugs in Development, 2021
Vasoactive Intestinal Polypeptide Receptor 2 (Helodermin Preferring VIP Receptor or Pituitary Adenylate Cyclase Activating Polypeptide Type III Recept...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drugs in Development, 2021
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD1...
Published: Apr-2021 | No. of Pages: 75
|
$ 3000 |